Cirrhosis

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver.

What is Cirrhosis?

Cirrhosis is a severe form of liver disease wherein normal liver tissue is replaced by scar tissue (fibrous tissue).

What Causes Cirrhosis?

Managing and Treating Cirrhosis

Liver Disease Symptoms

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025

£2.2 million grant supports clinical trials for liver dialysis device

Clinical trials to continue the development of a liver dialysis device to treat those with life-threatening liver disease have been funded by a grant awarded to UCL, the Royal Free Hospital and Yaqrit.

21 Mar 2025

Review explores the underlying mechanisms of hepatocarcinogenesis post-HCV eradication

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.

20 Mar 2025

Researchers move closer to a functional cure for chronic hepatitis B

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

17 Mar 2025

Impact of excessive alcohol consumption on digestive health

Excessive alcohol consumption is a significant public health concern, responsible for approximately 6% of all deaths and contributing to 5.1% of the global disease burden.

12 Mar 2025

Nwd1 gene linked to liver dysfunction in metabolic disease

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

11 Mar 2025

Study reveals the role of transcription factors as therapeutic gateways in MAFLD

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer.

11 Mar 2025

Existing drug could prevent liver damage caused by ammonia build-up

High levels of ammonia kill liver cells by damaging the mitochondria that power the cells. But this can be prevented using an existing drug due to start clinical trials, finds a new study in mice led by researchers from UCL.

7 Mar 2025

Asah1 gene plays key role in preventing progression of nonalcoholic fatty liver disease

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by regulating hepatic lipid homeostasis and cellular maintenance processes.

6 Mar 2025

New drug candidate may help combat metabolic dysfunction-associated steatotic liver disease

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that disproportionately affects communities in San Antonio due to high rates of obesity and diabetes.

5 Mar 2025

Understanding the impact of SLC transporters on liver disease progression

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.

28 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

Vitamin E significantly improves liver health in MASH patients, new study finds

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in patients with MASH, with no major safety concerns reported.

19 Feb 2025

Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

19 Feb 2025

Traffic-related air pollution may raise the risk of metabolic-associated fatty liver disease

Long-term exposure to low levels of traffic-related air pollution harms the liver and may raise the risk of metabolic-associated fatty liver disease, a new study in mice suggests.

31 Jan 2025

HMB supplement trial explores new treatment for chronic liver disease

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

28 Jan 2025

Bariatric surgery reduces liver complications in obese patients with cirrhosis

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver complications compared with patients who received medical therapy alone.

27 Jan 2025

CDC report reveals COPD as the sixth leading cause of death in the U.S.

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of death in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).

21 Jan 2025

Evaluating biomarkers for diagnosing minimal hepatic encephalopathy in cirrhotic patients

The performance of neurodegenerative biomarkers-neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1)-in diagnosing minimal hepatic encephalopathy (MHE) has not been systematically evaluated, simultaneously, nor have their associations with the development of overt hepatic encephalopathy (OHE).

17 Jan 2025

Exploring the role of EpCAM in early-stage hepatocellular carcinoma progression

Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors.

17 Jan 2025

Cirrhosis

Overview

What Causes Cirrhosis?

Managing and Treating Cirrhosis

Liver Disease Symptoms

Latest Cirrhosis News and Research

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

£2.2 million grant supports clinical trials for liver dialysis device

Review explores the underlying mechanisms of hepatocarcinogenesis post-HCV eradication

Researchers move closer to a functional cure for chronic hepatitis B

Impact of excessive alcohol consumption on digestive health

Nwd1 gene linked to liver dysfunction in metabolic disease

Study reveals the role of transcription factors as therapeutic gateways in MAFLD

Existing drug could prevent liver damage caused by ammonia build-up

Asah1 gene plays key role in preventing progression of nonalcoholic fatty liver disease

New drug candidate may help combat metabolic dysfunction-associated steatotic liver disease

Understanding the impact of SLC transporters on liver disease progression

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Vitamin E significantly improves liver health in MASH patients, new study finds

Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinoma

Traffic-related air pollution may raise the risk of metabolic-associated fatty liver disease

HMB supplement trial explores new treatment for chronic liver disease

Bariatric surgery reduces liver complications in obese patients with cirrhosis

CDC report reveals COPD as the sixth leading cause of death in the U.S.

Evaluating biomarkers for diagnosing minimal hepatic encephalopathy in cirrhotic patients

Exploring the role of EpCAM in early-stage hepatocellular carcinoma progression

In the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic Immunotherapy

Making Complex Cell Culture Easy and Efficient with AI

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Cirrhosis

Overview

Latest Cirrhosis News and Research

In the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic Immunotherapy

Making Complex Cell Culture Easy and Efficient with AI

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Newsletters you may be interested in